{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:41:14Z","timestamp":1792806074064,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T00:00:00Z","timestamp":1599696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T00:00:00Z","timestamp":1599696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI12660101"],"award-info":[{"award-number":["AI12660101"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI12660101"],"award-info":[{"award-number":["AI12660101"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:italic>Burkholderia mallei<\/jats:italic> (<jats:italic>Bm<\/jats:italic>) is a facultative intracellular pathogen and the etiological agent of glanders, a highly infectious zoonotic disease occurring in equines and humans. The intrinsic resistance to antibiotics, lack of specific therapy, high mortality, and history as a biothreat agent, prompt the need of a safe and effective vaccine. However, the limited knowledge of protective <jats:italic>Bm<\/jats:italic>-specific antigens has hampered the development of a vaccine. Further, the use of antigen-delivery systems that enhance antigen immunogenicity and elicit robust antigen-specific immune responses has been limited and could improve vaccines against <jats:italic>Bm<\/jats:italic>. Nanovaccines, in particular gold nanoparticles (AuNPs), have been investigated as a strategy to broaden the repertoire of vaccine-mediated immunity and as a tool to produce multivalent vaccines. To synthesize a nano-glycoconjugate vaccine, six predicted highly immunogenic antigens identified by a genome-wide bio- and immuno-informatic analysis were purified and coupled to AuNPs along with lipopolysaccharide (LPS) from <jats:italic>B. thailandensis<\/jats:italic>. Mice immunized intranasally with individual AuNP-protein-LPS conjugates, showed variable degrees of protection against intranasal <jats:italic>Bm<\/jats:italic> infection, while an optimized combination formulation (containing protein antigens OmpW, OpcP, and Hemagglutinin, along with LPS) showed complete protection against lethality in a mouse model of inhalational glanders. Animals immunized with different nano-glycoconjugates showed robust antigen-specific antibody responses. Moreover, serum from animals immunized with the optimized nano-glycoconjugate formulation showed sustained antibody responses with increased serum-mediated inhibition of adherence and opsonophagocytic activity in vitro. This study provides the basis for the rational design and construction of a multicomponent vaccine platform against <jats:italic>Bm<\/jats:italic>.<\/jats:p>","DOI":"10.1038\/s41541-020-00229-9","type":"journal-article","created":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T10:05:20Z","timestamp":1599732320000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Multicomponent gold nano-glycoconjugate as a highly immunogenic and protective platform against Burkholderia mallei"],"prefix":"10.1038","volume":"5","author":[{"given":"Daniel","family":"Tapia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier I.","family":"Sanchez-Villamil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6450-0643","authenticated-orcid":false,"given":"Alfredo G.","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,10]]},"reference":[{"key":"229_CR1","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1146\/annurev.micro.112408.134030","volume":"64","author":"EE Galyov","year":"2010","unstructured":"Galyov, E. E., Brett, P. J. & DeShazer, D. Molecular insights into Burkholderia pseudomallei and Burkholderia mallei pathogenesis. Annu. Rev. Microbiol. 64, 495\u2013517 (2010).","journal-title":"Annu. Rev. Microbiol."},{"key":"229_CR2","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1080\/14712598.2019.1677602","volume":"19","author":"D Tapia","year":"2019","unstructured":"Tapia, D., Sanchez-Villamil, J. I. & Torres, A. G. Emerging role of biologics for the treatment of melioidosis and glanders. Expert Opin. Biol. Ther. 19, 1319\u20131332 (2019).","journal-title":"Expert Opin. Biol. Ther."},{"key":"229_CR3","unstructured":"Khakhum, N., Tapia, D. & Torres, A. G. In Defense Against Biological Attacks. Vol. II (eds S.K. Singh & J.H. Kuhn) 185\u2013212. (Springer Nature, 2019)."},{"key":"229_CR4","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1586\/14760584.2016.1170598","volume":"15","author":"SA Aschenbroich","year":"2016","unstructured":"Aschenbroich, S. A., Lafontaine, E. R. & Hogan, R. J. Melioidosis and glanders modulation of the innate immune system: barriers to current and future vaccine approaches. Expert Rev. Vaccines 15, 1163\u20131181 (2016).","journal-title":"Expert Rev. Vaccines"},{"key":"229_CR5","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1586\/eri.10.4","volume":"8","author":"DM Estes","year":"2010","unstructured":"Estes, D. M., Dow, S. W., Schweizer, H. P. & Torres, A. G. Present and future therapeutic strategies for melioidosis and glanders. Expert Rev. Anti Infect. Ther. 8, 325\u2013338 (2010).","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"229_CR6","doi-asserted-by":"publisher","first-page":"570","DOI":"10.2460\/javma.233.4.570","volume":"233","author":"GD Dvorak","year":"2008","unstructured":"Dvorak, G. D. & Spickler, A. R. Glanders. J. Am. Vet. Med Assoc. 233, 570\u2013577 (2008).","journal-title":"J. Am. Vet. Med Assoc."},{"key":"229_CR7","doi-asserted-by":"publisher","first-page":"17107","DOI":"10.1038\/nrdp.2017.107","volume":"4","author":"WJ Wiersinga","year":"2018","unstructured":"Wiersinga, W. J. et al. Melioidosis. Nat. Rev. Dis. Prim. 4, 17107 (2018).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"229_CR8","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/j.1865-1682.2012.01342.x","volume":"60","author":"I Khan","year":"2013","unstructured":"Khan, I. et al. Glanders in animals: a review on epidemiology, clinical presentation, diagnosis and countermeasures. Transbound. Emerg. Dis. 60, 204\u2013221 (2013).","journal-title":"Transbound. Emerg. Dis."},{"key":"229_CR9","doi-asserted-by":"publisher","first-page":"5981","DOI":"10.1016\/j.vaccine.2017.03.022","volume":"35","author":"RW Titball","year":"2017","unstructured":"Titball, R. W., Burtnick, M. N., Bancroft, G. J. & Brett, P. Burkholderia pseudomallei and Burkholderia mallei vaccines: Are we close to clinical trials? Vaccine 35, 5981\u20135989 (2017).","journal-title":"Vaccine"},{"key":"229_CR10","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1128\/IAI.00328-16","volume":"84","author":"CL Hatcher","year":"2016","unstructured":"Hatcher, C. L., Mott, T. M., Muruato, L. A., Sbrana, E. & Torres, A. G. Burkholderia mallei CLH001 attenuated vaccine strain is immunogenic and protects against acute respiratory glanders. Infect. Immun. 84, 2345\u20132354 (2016).","journal-title":"Infect. Immun."},{"key":"229_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0007578","volume":"13","author":"N Khakhum","year":"2019","unstructured":"Khakhum, N. et al. Evaluation of Burkholderia mallei \u0394tonB \u0394hcp1 (CLH001) as a live attenuated vaccine in murine models of glanders and melioidosis. PLoS Negl. Trop. Dis. 13, e0007578 (2019).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"229_CR12","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.drudis.2011.04.006","volume":"16","author":"ML De Temmerman","year":"2011","unstructured":"De Temmerman, M. L. et al. Particulate vaccines: on the quest for optimal delivery and immune response. Drug Disco. Today 16, 569\u2013582 (2011).","journal-title":"Drug Disco. Today"},{"key":"229_CR13","doi-asserted-by":"publisher","first-page":"151","DOI":"10.4155\/tde-2016-0068","volume":"8","author":"N Marasini","year":"2017","unstructured":"Marasini, N., Skwarczynski, M. & Toth, I. Intranasal delivery of nanoparticle-based vaccines. Ther. Deliv. 8, 151\u2013167 (2017).","journal-title":"Ther. Deliv."},{"key":"229_CR14","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.molimm.2017.09.001","volume":"91","author":"S Ahmad","year":"2017","unstructured":"Ahmad, S. et al. Targeting dendritic cells through gold nanoparticles: a review on the cellular uptake and subsequent immunological properties. Mol. Immunol. 91, 123\u2013133 (2017).","journal-title":"Mol. Immunol."},{"key":"229_CR15","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jconrel.2017.04.024","volume":"256","author":"S Kang","year":"2017","unstructured":"Kang, S. et al. Effects of gold nanoparticle-based vaccine size on lymph node delivery and cytotoxic T-lymphocyte responses. J. Control Release 256, 56\u201367 (2017).","journal-title":"J. Control Release"},{"key":"229_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.201701395","volume":"7","author":"LC Lin","year":"2018","unstructured":"Lin, L. C., Chattopadhyay, S., Lin, J. C. & Hu, C. J. Advances and opportunities in nanoparticle- and nanomaterial-based vaccines against bacterial infections. Adv. Health. Mater. 7, e1701395 (2018).","journal-title":"Adv. Health. Mater."},{"key":"229_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/mBio.01869-19","volume":"10","author":"JI Sanchez-Villamil","year":"2019","unstructured":"Sanchez-Villamil, J. I., Tapia, D. & Torres, A. G. Development of a gold nanoparticle vaccine against enterohemorrhagic Escherichia coli O157:H7. mBio 10, 1\u201316 (2019).","journal-title":"mBio"},{"key":"229_CR18","doi-asserted-by":"publisher","first-page":"pii: e00206-002","DOI":"10.1128\/CVI.00206-17","volume":"24","author":"LA Muruato","year":"2017","unstructured":"Muruato, L. A. et al. Use of reverse vaccinology in the design and construction of nanoglycoconjugate vaccines against Burkholderia pseudomallei. Clin. Vaccin. Immunol. 24, pii: e00206-00217 (2017).","journal-title":"Clin. Vaccin. Immunol."},{"key":"229_CR19","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1039\/df9511100055","volume":"11","author":"J Turkevich","year":"1951","unstructured":"Turkevich, J., Stevenson, P. C. & Hillier, J. A study of the nucleation and growth process in the synthesis of colloidal gold. Discuss Faraday Soc. 11, 55\u201375 (1951).","journal-title":"Discuss Faraday Soc."},{"key":"229_CR20","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jim.2010.02.007","volume":"356","author":"S Thobhani","year":"2010","unstructured":"Thobhani, S. et al. Bioconjugation and characterisation of gold colloid-labelled proteins. J. Immunol. Methods 356, 60\u201369 (2010).","journal-title":"J. Immunol. Methods"},{"key":"229_CR21","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/nri2868","volume":"10","author":"MF Bachmann","year":"2010","unstructured":"Bachmann, M. F. & Jennings, G. T. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat. Rev. Immunol. 10, 787\u2013796 (2010).","journal-title":"Nat. Rev. Immunol."},{"key":"229_CR22","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.nano.2017.11.009","volume":"14","author":"N Climent","year":"2018","unstructured":"Climent, N. et al. Loading dendritic cells with gold nanoparticles (GNPs) bearing HIV-peptides and mannosides enhance HIV-specific T cell responses. Nanomedicine 14, 339\u2013351 (2018).","journal-title":"Nanomedicine"},{"key":"229_CR23","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00692-19","volume":"87","author":"S Sengyee","year":"2019","unstructured":"Sengyee, S., Yoon, S. H., West, T. E., Ernst, R. K. & Chantratita, N. Lipopolysaccharides from different Burkholderia species with different lipid A structures induce toll-Like receptor 4 activation and react with melioidosis patient sera. Infect. Immun. 87, e00692-00619 (2019).","journal-title":"Infect. Immun."},{"key":"229_CR24","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1038\/nm.2535","volume":"17","author":"FY Avci","year":"2011","unstructured":"Avci, F. Y., Li, X., Tsuji, M. & Kasper, D. L. A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design. Nat. Med. 17, 1602\u20131609 (2011).","journal-title":"Nat. Med."},{"key":"229_CR25","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1128\/IAI.74.3.1944-1948.2006","volume":"74","author":"DM Waag","year":"2006","unstructured":"Waag, D. M., McCluskie, M. J., Zhang, N. & Krieg, A. M. A CpG oligonucleotide can protect mice from a low aerosol challenge dose of Burkholderia mallei. Infect. Immun. 74, 1944\u20131948 (2006).","journal-title":"Infect. Immun."},{"key":"229_CR26","doi-asserted-by":"publisher","first-page":"3341","DOI":"10.1016\/j.vaccine.2010.08.002","volume":"29","author":"F Steinhagen","year":"2011","unstructured":"Steinhagen, F., Kinjo, T., Bode, C. & Klinman, D. M. TLR-based immune adjuvants. Vaccine 29, 3341\u20133355 (2011).","journal-title":"Vaccine"},{"key":"229_CR27","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1021\/pr1012398","volume":"10","author":"MA Schell","year":"2011","unstructured":"Schell, M. A., Zhao, P. & Wells, L. Outer membrane proteome of Burkholderia pseudomallei and Burkholderia mallei from diverse growth conditions. J. Proteome Res. 10, 2417\u20132424 (2011).","journal-title":"J. Proteome Res."},{"key":"229_CR28","first-page":"148","volume":"2","author":"MN Burtnick","year":"2012","unstructured":"Burtnick, M. N., Heiss, C., Schuler, A. M., Azadi, P. & Brett, P. J. Development of novel O-polysaccharide based glycoconjugates for immunization against glanders. Front Cell Infect. Microbiol 2, 148 (2012).","journal-title":"Front Cell Infect. Microbiol"},{"key":"229_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-48828-4","volume":"9","author":"A Pumpuang","year":"2019","unstructured":"Pumpuang, A. et al. Distinct classes and subclasses of antibodies to hemolysin co-regulated protein 1 and O-polysaccharide and correlation with clinical characteristics of melioidosis patients. Sci. Rep. 9, 13972 (2019).","journal-title":"Sci. Rep."},{"key":"229_CR30","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.nano.2014.08.005","volume":"11","author":"AE Gregory","year":"2015","unstructured":"Gregory, A. E. et al. A gold nanoparticle-linked glycoconjugate vaccine against Burkholderia mallei. Nanomedicine 11, 447\u2013456 (2015).","journal-title":"Nanomedicine"},{"key":"229_CR31","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s002510050258","volume":"46","author":"RM Martin","year":"1997","unstructured":"Martin, R. M., Silva, A. & Lew, A. M. The Igh-1 sequence of the non-obese diabetic (NOD) mouse assigns it to the IgG2c isotype. Immunogenetics 46, 167\u2013168 (1997).","journal-title":"Immunogenetics"},{"key":"229_CR32","doi-asserted-by":"publisher","unstructured":"Nazeri, S., Zakeri, S., Mehrizi, A. A., Sardari, S. & Djadid, N. D. Measuring of IgG2c isotype instead of IgG2a in immunized C57BL\/6 mice with Plasmodium vivax TRAP as a subunit vaccine candidate in order to correct interpretation of Th1 versus Th2 immune response. Exp. Parasitol., https:\/\/doi.org\/10.1016\/j.exppara.2020.107944 (2020).","DOI":"10.1016\/j.exppara.2020.107944"},{"key":"229_CR33","doi-asserted-by":"publisher","unstructured":"Muruato, L. A. et al. Use of reverse vaccinology in the design and construction of nanoglycoconjugate vaccines against Burkholderia pseudomallei. Clin. Vaccine Immunol. 24, https:\/\/doi.org\/10.1128\/CVI.00206-17 (2017).","DOI":"10.1128\/CVI.00206-17"},{"key":"229_CR34","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods 9, 676\u2013682 (2012).","journal-title":"Nat. Methods"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-020-00229-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-020-00229-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-020-00229-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T03:42:10Z","timestamp":1670298130000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-020-00229-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,10]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["229"],"URL":"https:\/\/doi.org\/10.1038\/s41541-020-00229-9","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,10]]},"assertion":[{"value":"15 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"82"}}